Background: A number of food allergies (eg, fish, shellfish, and nuts) are lifelong, without any disease-transforming therapies, and unclear in their underlying immunology. Clinical manifestations of food allergy are largely mediated by IgE. Although persistent IgE titers have been attributed conventionally to long-lived IgE 1 plasma cells (PCs), this has not been directly and comprehensively tested. Objective: We sought to evaluate mechanisms underlying persistent IgE and allergic responses to food allergens. Methods: We used a model of peanut allergy and anaphylaxis, various knockout mice, adoptive transfer experiments, and in vitro assays to identify mechanisms underlying persistent IgE humoral immunity over almost the entire lifespan of the mouse (18-20 months) . Results: Contrary to conventional paradigms, our data show that clinically relevant lifelong IgE titers are not sustained by long-lived IgE 1 PCs. Instead, lifelong reactivity is conferred by allergen-specific long-lived memory B cells that replenish the IgE 1 PC compartment. B-cell reactivation requires allergen re-exposure and IL-4 production by CD4 T cells. We define the half-lives of antigen-specific germinal centers (23.3 days), IgE Food allergy is typified by pathogenic T H 2 responses and is of growing clinical and public concern. [1] [2] [3] The clinical manifestations of type 1 hypersensitivity reactions to foods are mediated by IgE cross-linking of antigen on mast cells (MCs) through FcεRI. 4, 5 Clinical symptoms and signs range in severity from mild urticaria, wheezing, vomiting, and diarrhea to anaphylaxis, a systemic reaction that is rapid in onset and life-threatening. 6 An issue of grave concern that remains poorly understood is that a number of food allergies (eg, fish, shellfish, tree nuts, and peanuts) 7, 8 are lifelong, and no disease-transforming therapies exist. In this study we investigated cellular processes underlying the persistence of IgE-mediated clinical reactivity in an established model of peanut allergy and anaphylaxis. [9] [10] [11] Current understanding on the maintenance of food allergy is predominantly extrapolated from immunity to viruses and vaccines 12 and proposes that after antigen-dependent T-cell interactions, germinal center (GC) B cells can generate high-affinity IgE-producing plasmablasts. 13, 14 Plasmablasts exit GCs and relocate to the bone marrow (BM), where they terminally differentiate into mitotically quiescent plasma cells (PCs) 15 and secrete IgE for the lifetime of the patient. [16] [17] [18] [19] Although the establishment of PCs in the BM on systemic and mucosal T H 2 immunization has been documented, [20] [21] [22] the lifespan of IgE-producing PCs remains poorly characterized, particularly as it refers to food allergens. This is in part due to the paucity of studies extending beyond 3 months after sensitization, as well as the historical methodological challenges of identifying rare populations of antigen-specific IgE 1 PCs. 19, 23 Importantly, the spatiotemporal distribution of memory B cells on T H 2 mucosal immunization and, particularly, their clinical relevance remain largely unexplored. 24 In this study we identified immunologic mechanisms underlying lifelong IgE responses with direct relevance to food allergy. Our data show that IgE-mediated clinical reactivity to peanut in allergic mice that remained unexposed to the allergen is not lifelong. However, the potential to develop anaphylaxis on peanut re-exposure is maintained for virtually the lifetime of the mouse because of long-lasting B-cell memory responses dependent on IL-4-producing CD4 T cells. Reactivated memory B cells regenerate the IgE 1 PC compartment with ensuing IgE production. We define the half-lives of antigen-specific GCs, IgE 1 and IgG 1 1 PCs, and clinically relevant cell-bound IgE. These data demonstrate that long-lived allergen-specific memory cells are critical in the maintenance of food allergy, and, consequently, identify this cell population as a key therapeutic target in IgE-mediated reactions.
METHODS
Supplemental information can be found in the Methods section in this article's Online Repository at www.jacionline.org.
Mice
Age-, sex-, vendor-, and strain-matched control animals were used in all the experiments. IgE-deficient mice (Igh-7 tm1Led ) 25 
Statistics
Half-life was calculated by using the following equation:
(Elapsed time 3 log 2 )/(log[beginning amount/ending amount]). 26 Data were analyzed and graphed with GraphPad Prism 6 software (GraphPad Software, La Jolla, Calif). Continuous data are expressed as means 6 SEMs and were analyzed by using 1-or 2-way ANOVA with Bonferroni post hoc tests and the unpaired Student t test. Differences were considered statistically significant at a P value of less than .05.
RESULTS

IgE-mediated clinical reactivity to food allergens wanes with time despite storage of IgE on MCs
We used a well-established model of food allergy that mimics multiple features of the human disease 4, [9] [10] [11] [27] [28] [29] [30] to evaluate the kinetics of clinical reactivity and circulating specific IgE and IgG 1 over time. Mice were sensitized to peanut, and then separate groups were challenged with the allergen at different times after (Fig 1, A) and hemoconcentration (Fig 1, B) . C and D, Serum peanut-specific IgE (Fig 1, C) and IgG 1 (Fig 1, D) before challenge. E, Correlation of serum peanut-specific immunoglobulins and clinical reactivity (hematocrit). Pooled data from 2 to 3 independent experiments and represented as means 6 SEMs (n 5 10-20). *P < .05 versus naive values.
sensitization for up to 15 months (approximately 75% of the lifespan of a mouse). 31 Each group was challenged only once. Anaphylaxis was assessed by measuring core temperature over 40 minutes (see Fig E1, A, in this article's Online Repository at www.jacionline.org), which was represented as the area under 398C for clarity (Fig 1, A , and see Fig E1, B) , and hematocrit (Fig 1, B) , with hemoconcentration indicating vascular leakage. On average, allergic mice experienced a 58C or greater decrease in core temperature and a 150% or greater increase in hematocrit level. Clinical reactivity remained significant for up to 6 months after sensitization.
Because anaphylaxis is mainly mediated by IgE and, to a lesser extent, IgG 1 , 4 we measured serum levels of peanut-specific IgE and IgG 1 by ELISA. Serum levels of peanut-specific IgE peaked at 2 weeks after sensitization and gradually decreased over time until becoming undetectable at 6 months after sensitization (Fig 1, C) . This correlated in a strong positive manner with clinical reactivity (R 2 5 0.923; Fig 1, E) . In contrast, sustained serum levels of peanut-specific IgG 1 were detected for up to 15 months after sensitization (Fig 1, D) and showed a weak positive correlation with clinical reactivity (R 2 5 0.159 ;  Fig 1, E) . and clinical reactivity was evaluated based on hypothermia (Fig 2, E) and hemoconcentration (Fig 2, F) . Pooled data from 2 to 3 independent experiments and presented as means 6 SEMs (n5 3-5 per experiment). *P < .05 versus naive values. FMO, Fluorescence minus one.
Paradoxically, when peanut-specific IgE was no longer significant in serum at 6 months after sensitization (Fig 1, C) , the mice still underwent severe anaphylaxis on challenge (Fig 1, A and B) . We hypothesized that this could be due to allergen cross-linking of cell-bound IgE. To test this, we generated a system to track the temporospatial distribution of IgE using serum transfer from wild-type (WT) allergic mice to IgE-deficient mice (Fig 2, A) . As shown in Fig 2, B, serum levels of peanut-specific IgE were increased at 6 hours after transfer, decreased by 24 and 48 hours, and were no longer detected after 168 hours (7 days). To determine whether the decrease in circulating peanut-specific IgE levels was due to the uptake of IgE by MCs, we measured MCbound IgE in recipient mice using flow cytometry (Fig 2, C) . As early as 6 hours after transfer, MCs in IgE-deficient animals were loaded with IgE, reaching almost 100% saturation by 24 hours. More than 70% of MCs were still coated with IgE 7 days after transfer (Fig 2, D) . Separate groups of IgE-deficient mice were passively immunized to peanut and challenged once at different times after transfer for up to 120 days to determine the duration of clinical reactivity caused by MC-bound IgE (Fig 2, E and F) . Clinical reactivity peaked 2 days after transfer and was comparable with that observed in actively immunized mice with peanut allergy (Fig 1, A and B) . From days 2 to 15, clinical reactivity decreased and reached a plateau that was maintained for up to 75 days; anaphylaxis was no longer evident after 100 days after transfer. These data provided a calculated half-life for MC-bound IgE-mediated reactivity of 67.3 days (95% CI, 46.5-88.1 days) and demonstrate that undetectable serum allergen-specific IgE does not preclude clinical reactivity on allergen exposure.
Persistent IgE production requires GC formation by Bcl-6-competent B cells
We sought to identify whether transient IgE titers were due to follicular or extrafollicular generation of antibody-producing cells. Affinity maturation resulting in sustained production of high-affinity antibodies occurs in GCs, and the binding affinity of IgE to allergen contributes to the severity of anaphylaxis. 13 To examine antigen-specific GC reactions during allergen sensitization, we used ovalbumin (OVA), a model antigen that can be easily tracked. We first verified that T H 2 humoral responses and clinical reactivity to OVA for up to 6 months after sensitization were comparable with those observed with peanut (see Fig E1, C-E). To quantify the duration of GC activity, we identified antigen-specific GC B cells using flow cytometry based on coexpression of CD95 and GL7 and binding to OVA (Fig 3, A) . OVA-specific GC B cells were present at 6 days after sensitization (Fig 3, B) and mLNs (Fig 3, C) at different times after sensitization.
D and E, Bcl-6 B-cell KO and WT mice were sensitized to peanut (PN), and anaphylaxis was evaluated based on hypothermia (Fig 3, D) and hemoconcentration (Fig 3, E) . F and G, Serum peanut-specific IgE (Fig 3, F) and IgG 1 (Fig 3, G) levels at different times after sensitization. Representative data from 2 to 3 independent experiments and represented as means 6 SEMs (n 5 4-6 per experiment). *P < .05 versus naive values. FMO, Fluorescence minus one; n.s., nonsignificant.
both in the spleen (Fig 3, B) and mesenteric lymph nodes (mLNs; Fig 3, C) , becoming undetectable by 34 days in the spleen (Fig 3, B) and 60 days in the mLNs (Fig 3, C) . The calculated half-life of GC reactions in this system is 23.3 days (95% CI, 12.6-34.0 days).
Development of GCs relies on the transcriptional repressor Bcl-6. 32, 33 To evaluate the role of GCs in allergen-specific antibody production and anaphylaxis, we investigated mice with a deficiency in Bcl-6 restricted to the B-cell lineage (Mb1-cre x BCL6 fl/fl , hereafter denoted as Bcl-6 B-cell knockout [KO] mice). Bcl-6 B-cell KO mice with peanut allergy reacted clinically to allergen challenge in a manner comparable with WT mice (Fig 3, D and E) . Serum levels of peanut-specific IgE (Fig 3, F) and IgG 1 (Fig 3, G) decreased significantly faster over time in B-cell KO mice compared with WT mice. These data suggest that extrafollicular antibody production can facilitate hypersensitivity reactions early after sensitization but that sustained humoral IgE/IgG 1 responses are dependent on GC-derived PCs.
Poor survival of cyclophosphamide-resistant antigen-specific IgE 1 PCs generated on sensitization to food allergens Systemic immunization with T H 2 adjuvants can lead to production of IgE 1 long-lived PCs that home to the BM, which have been examined up to 80 days after sensitization. 22 To directly identify antigen-specific IgE 1 PCs elicited by intestinal allergic sensitization, we took advantage of a recently validated flow cytometric method.
14 Our gating strategy and in-house revalidation are shown in Fig 4, A, and Fig E2, A, in this article's Online Repository at www.jacionline.org. We evaluated antigen-specific IgE 1 or IgG1 1 PCs in the mLNs, lamina propria (LP) of the small intestine, spleen, and BM for up to 9 months after immunization. At 1 month after sensitization, we detected significant percentages of antigen-specific IgG 1 1 PCs in the mLNs (see Fig E2, B) and antigen-specific IgE 1 or IgG 1 1 PCs in the BM (Fig 4, B) . Neither population was detected in the spleen or LP of the small intestine (data not shown). In the mLNs percentages of antigen-specific IgG 1 1 PCs decreased A-C, Antigen-specific IgE 1 /IgG 1 1 PCs were identified in BM by using flow cytometry (Fig 4, A) and assessed at different times after sensitization (Fig 4, B and C) . D, Separate groups of mice were sensitized to peanut (PN); treated with CYC, BZ, or a vehicle control (VEH); and later challenged. E, F, I, and J, Peanut-specific IgE/IgG 1 with and without CYC (Fig 4 , E and F) or BZ (Fig 4, I and J). G, H, K, and L, Anaphylaxis-induced hypothermia (Fig 4 , G and K) and hemoconcentration (Fig 4 over time until becoming undetectable by 3 months after sensitization (see Fig E2, B) . In the BM antigen-specific IgE PCs were detected for up to 3 months after sensitization (Fig 4,  B) , which is in agreement with the kinetics of peanut-specific IgE in serum (Fig 1, C) ; the calculated half-life for antigen-specific IgE 1 BM PCs is 60 days (95% CI, 27-93 days). In contrast, antigen-specific IgG 1 1 BM PCs were detected for at least 9 months after sensitization (Fig 4, C) , which is also consistent with the antigen-specific IgG 1 titer in serum (Fig 1, D) ; the calculated half-life of antigen-specific IgG 1 1 BM PCs is 234.4 days (95% CI, 45.7-426.1 days).
Long-lived PCs are mitotically quiescent cells, which are classically defined by their resistance to cytotoxic agents, such as cyclophosphamide (CYC), a chemotherapeutic drug that kills proliferating cells. 34 Bortezomib (BZ) is a 20S proteasome inhibitor that eliminates cells that produce high amounts of proteins, notably PCs. 35 Therefore mice were treated with either CYC or BZ once GC activity had ended (2.5 months after sensitization) to determine whether the BM-resident PC population generated on mucosal T H 2 immunization was proliferating (short-lived) or nondividing (long-lived). 15 In agreement with previous studies, BZ treatment depleted PCs in the BM (see Fig  E3, A and B, in this article's Online Repository at www. jacionline.org) and spleen (see Fig E3, C and D) , whereas CYC treatment dramatically reduced both the B-and T-cell compartments (see Fig E3, E-G ). Mice were sensitized to peanut and then treated with either CYC or BZ when GC activity had ended (2.5 months after sensitization). After these treatments, mice were left unmanipulated for 100 days, allowing for clinical reactivity caused by cell-bound IgE to wane, and then challenged with allergen (Fig 4, D) . Compared with vehicle-treated mice, serum levels of peanut-specific IgE (Fig 4, E) and IgG 1 (Fig 4, F) after CYC treatment (1-2 weeks after treatment) were not affected, and CYC-treated mice exhibited full anaphylaxis with BZ were exposed to peanut either mucosally or systemically and challenged 2 weeks later. B and C, Serum peanut-specific IgE (Fig 5, B) and IgG 1 (Fig 5, C) . D and E, Anaphylaxis-induced hypothermia (Fig 5, D) and hemoconcentration (Fig 5, E) after challenge. Mice were sensitized and 8 months later were either left unmanipulated or re-exposed to oral allergen before analysis at 9 months. F-L, Gating strategy and identification of antigen-specific IgE 1 /IgG 1 1 memory B cells in LP of the small intestine, mLNs, and spleen. M-P, Antigen-specific PCs in BM (Fig 5, M and N) and serum antigen-specific IgE (Fig 5, O) and IgG 1 (Fig 5, P) . Values are presented as means 6 SEMs (n 5 9-15 pooled from 2-3 experiments). *P < .05 versus naive values. FMO, Fluorescence minus one; n.s., nonsignificant.
on challenge (Fig 4, G and H) . In contrast, BZ treatment exhibited greatly reduced serum levels of peanut-specific IgE (Fig 4, I ) and IgG 1 (Fig 4, J) . Accordingly, BZ-treated mice did not experience anaphylaxis on allergen challenge (Fig 4, K and L) . Treatment with BZ immediately after sensitization was ineffective because of ongoing GC activity (see Fig E3, H-J), and challenge immediately after BZ treatment did not impair clinical reactivity because of residual cell-bound IgE (Fig 2, E and F, and see Fig E3, K-M ). These data demonstrate the existence of cytotoxic-resistant, antigen-specific IgE 1 long-lived PCs in the BM, which have a much shorter half-life compared with IgG 1 1 PCs of the same antigen specificity.
Allergen re-exposure activates long-lived memory B cells to reinvigorate IgE humoral immunity
We questioned whether the abrogation of clinical reactivity on PC depletion was due to a transient or permanent elimination of IgE humoral immunity. To test this, mice with peanut allergy were treated with BZ at 2.5 months after sensitization to deplete PCs, rested for 100 days to allow for reactivity because of MC-bound IgE to wane, and then challenged. Some mice received allergen orally, which, in the absence of adjuvant, will not drive a primary immune response (Fig 5, A) . Re-exposure to allergen at this time did not induce any anaphylactic reactions (data not shown). Serum levels of peanut-specific IgE (Fig 5, B) and IgG 1 (Fig 5, C) were assessed 2 weeks after allergen re-exposures. Peanutspecific IgE and IgG 1 were undetectable in BZ-treated mice that had not been re-exposed to allergen. In contrast, serum levels of peanut-specific IgE/IgG 1 were increased in BZ-treated mice that had been re-exposed to peanut either systemically or mucosally. Notably, when these mice were later challenged with peanut, the mice underwent severe anaphylaxis (Fig 5, D  and E) . Thus clinically silent allergen re-exposure of previously allergic mice fully regenerates disease expression.
The rapid appearance of circulating peanut-specific IgE/IgG 1 on allergen re-exposure in BZ-treated mice suggested that a memory response was triggered. To assess this, we evaluated antigen-specific IgE 1 and IgG 1 1 memory B cells (Fig 5, F) in the LP of the small intestine, mLNs, and spleens at 9 months after sensitization (Fig 5, G-I) . Although antigen-specific IgE 1 memory B cells were undetectable (data not shown), antigenspecific IgG 1 1 memory B cells were abundant in the LP of the small intestine (Fig 5, G) and in lower numbers in the mLNs (Fig 5, H) and spleen (Fig 5, I) .
Allergic mice were given antigen orally because it leads to tolerance (in the absence of adjuvant) 36 and therefore does not stimulate de novo sensitization to test the effect of allergen reexposure on the memory B-cell compartment. Oral allergen exposure induced antigen-specific IgG 1 1 memory B-cell expansion in the LP of the small intestine (Fig 5, G) , mLNs (Fig  5, H) , and spleen (Fig 5, I) ; in addition, a number of antigenspecific, IgE-expressing B cells became apparent (Fig 5, J-L) . Likewise, antigen-specific IgE 1 PCs, which were not present in the BM at 9 months after sensitization, repopulated the BM after allergen exposure (Fig 5, M) . In contrast, antigen-specific IgG 1
1
PCs were still present in the BM at 9 months and remained unchanged after allergen exposure (Fig 5, N) . The repopulation of the BM with antigen-specific IgE 1 PCs resulted in the emergence of high levels of antigen-specific IgE in the systemic circulation (Fig 5, O) , whereas antigen-specific IgG 1 remained at a stable and increased level (Fig 5, P) . These data show that T H 2 mucosal immunization results in establishment of both systemic and local long-lived allergen-specific memory B cells.
IgE production on recall relies on memory B-cell responses and IL-4-producing CD4 T cells
To further investigate the persistence of the memory response to allergen re-exposure, we extended our observation period until . Memory responses to peanut at 15 months after sensitization. Mice were sensitized to peanut (PN), rested for 15 months, and then re-exposed to peanut either mucosally or systemically before challenge to peanut 2 weeks later. A and B, Serum peanut-specific IgE (Fig 6, A) and IgG 1 (Fig 6, B) before challenge. C and D, Anaphylaxis-induced hypothermia (Fig 6, C) and hemoconcentration (Fig 6, D) . E-G, Proliferation of memory B cells (Fig 6, E) and CD4 T cells (Fig 6, F) and plasmablasts (Fig 6, G ) from spleens at 15 months. H and I, T H 2 cytokines from culture supernatants (Fig 6, H and I) . Values are presented as means 6 SEMs (n 5 8-15 pooled from 2-3 experiments). *P < .05 versus naive values. n.s., Nonsignificant.
the mice were 18 months of age or older (>75% of the lifespan of a mouse). Peanut-sensitized mice were re-exposed to peanut allergen either systemically or mucosally at 15 months after sensitization. Peanut-specific IgE was undetected at 15 months after sensitization, but levels increased rapidly 2 weeks after oral allergen re-exposure (Fig 6, A) , whereas serum levels of peanutspecific IgG 1 remained increased for the lifespan of the mice (Fig 6, B) . Soy exposure at regular intervals in these experiments did not appear to cause cross-reactivity or perpetuate allergy. Sensitized mice not re-exposed to peanut for more than 15 months did not clinically react to challenge (Fig 6, C and D) . In contrast, mice that had been re-exposed to peanut at 15 months after sensitization exhibited a full anaphylactic reaction when challenged (Fig 6, C and D) .
Splenocytes from peanut-allergic mice were carboxyfluorescein succinimidyl ester (CFSE) labeled and cultured with peanut to evaluate proliferation of memory B and CD4 T cells and plasmablasts by using flow cytometry to gain further insights into memory lymphocyte responses at this time (Fig 6, E-G) . We observed significant increases in proliferation of memory B and CD4 T cells (Fig 6, E and F) , as well as plasmablasts (Fig 6, G) , in response to peanut exposure at 15 months after sensitization. In addition, stimulation of these cells caused production of the hallmark T H 2 cytokines IL-4 and IL-5 (Fig 6,  H and I) . Therefore allergen-specific memory B and CD4 T cells established during mucosal immunization can last for a lifetime.
Whether memory humoral responses require T-cell help is contentious, 37, 38 including the requirement for IL-4 in secondary FIG 7 . IgE production on recall relies on memory B-cell responses and IL-4-producing CD4 T cells. A, Spleen cells from allergic mice were adoptively transferred into immunodeficient mice, and then recipients were exposed to oral allergen for 3 weeks. B and C, Serum antigen-specific IgE (Fig 7, B) and IgG 1 (Fig 7, C) . D and E, Anaphylaxis-induced hypothermia (Fig 7, D) and hemoconcentration (Fig 7, E) . F and G, Proliferation of memory B cells (Fig 7, F) and plasmablasts (Fig 7, G) IgE responses. 39, 40 To evaluate the contribution of memory CD4 T cells to secondary B-cell responses to food allergens, we developed an in vivo model to adoptively transfer immune memory. WT allergic mice were treated with depleting anti-CD4 antibody or vehicle between 1 and 3 months after sensitization; splenocytes from either of these donors were then transferred into immunodeficient Rag2 2/2 gc 2/2 recipients (Fig 7, A) , which lack T, B, and natural killer cells. The extent of CD4 T-cell depletion achieved with anti-CD4 reached greater than 99% in both the spleens (see Fig E4, A, in this article's Online Repository at www. jacionline.org) and LP of the small intestines (see Fig E4, B) of donor mice. Treatment with anti-CD4 was continued in the recipient mice after adoptive transfer, which were orally exposed to antigen 3 times a week for 3 weeks, followed by allergen challenge (Fig 7, A) . As expected, after allergen exposure, serum levels of antigen-specific IgE and IgG 1 (Fig 7, B and C) were increased in mice that received splenocytes from allergic mice. Importantly, mice that received sensitized splenocytes depleted of CD4 T cells did not generate antigen-specific IgE and IgG 1 after allergen exposure (Fig 7, B and C) . Consistent with these observations, anaphylaxis was observed in mice that received splenocytes from sensitized mice but not in those depleted of CD4 T cells (Fig 7, D and E) . These data show that CD4 T cell help is required to replenish IgE/IgG 1 humoral immunity during recall responses after allergen exposure in vivo.
We next investigated mechanisms of CD4 T cell help during secondary B-cell responses to food allergens. To address this, mice with peanut allergy were treated with depleting anti-CD4 antibody or vehicle in vivo before their splenocytes were labeled with CFSE and stimulated ex vivo with peanut in the presence of blocking antibodies to IL-4, CD40 ligand (CD40L), and/or an isotype control. CD4 T cells facilitated proliferation of memory B cells on allergen stimulation in an IL-4-and CD40L-independent manner (Fig 7, D , and see Fig E4, C and  D) . However, the lack of CD4 T cells, IL-4, or both reduced remarkably the frequency of proliferating plasmablasts (Fig 7,  G , and see Fig E4, E and F) . These data indicate that CD4 T H 2 cells provide critical help for the differentiation of proliferating memory B cells into plasmablasts through IL-4 secretion and independently of CD40L interactions.
DISCUSSION
Deciphering the generation and maintenance of food allergy in human subjects is challenging given that the critical events underlying these processes are clinically silent and occur in inaccessible tissues. Furthermore, inadvertent subclinical allergen exposure cannot be controlled. In this study we used an established model of peanut allergy and anaphylaxis to delineate the determinants of persistent IgE responses.
We found that clinical reactivity to food allergens is not lifelong because serum levels of allergen-specific IgE, the key effector molecule in anaphylaxis, disappeared over time. However, anaphylactic reactions persisted in the absence of detectable IgE. Kubo et al 41 reported severe anaphylaxis in B celldeficient mice challenged with TNP-BSA 56 days after transfer of TNP-IgE but did not precisely define the duration of reactivity caused by cell-bound IgE. Using a serum transfer approach, we determined that MCs remained loaded with clinically relevant levels of IgE, even in the absence of detectable serum IgE. Anaphylactic reactions to allergen in the absence of circulating IgE lasted 100 days (half-life: 67.3 days). These findings explain why a proportion of patients with clinical allergy paradoxically have undetectable levels of serum allergen-specific IgE.
We showed that T H 2 mucosal sensitization entailed GC activity, which, in turn, has been implicated in the generation of high-affinity antibodies. 42 Serum levels of peanut-specific IgE peaked earlier than those of IgG 1 , likely because of the predisposition of IgE 1 B cells to commit to a PC fate. 14 The genetic deletion of GC B cells did not affect early humoral responses or clinical reactivity. However, serum titers of specific IgE/IgG 1 decreased rapidly over time as a result of this GC-independent humoral response, which is consistent with the short-lived nature of extrafollicular PCs. 43, 44 These data suggest that the extrafollicular pathway can produce IgE of sufficient affinity to cause anaphylaxis plausibly through random generation of B-cell clones that, without further B-cell receptor editing, have high enough affinity toward food allergens to elicit anaphylaxis. In addition, because peanut is a complex matrix comprising multivalent allergens, 45 it is possible that IgE avidity contributes to the ability of the lower affinity of antibodies to cause pathology.
T H 2 mucosal sensitization produced antigen-specific IgE 1 PCs that homed to the BM. Although the majority of IgE 1 PCs are thought to be short-lived, 14 we demonstrated that a population of cytotoxic-resistant and, consequently, long-lived antigen-specific IgE 1 PCs were generated by means of allergic sensitization. This population is thought to be responsible for persistent IgE responses. [16] [17] [18] Using a comprehensive approach that integrated direct identification of antigen-specific IgE 1 PCs, measurement of antigen-specific IgE levels in serum, and clinical readouts, we determined that the half-lives of these cells were substantially shorter (half-life: 60 days) than previously proposed. 16, 18 This is in contrast to antigen-specific IgG 1 1 PCs, the half-lives of which we calculated to be 234. 4 We showed that mice became clinically nonreactive to allergen challenge after either natural or drug-induced extinction of allergen-specific IgE 1 PCs. However, mice underwent severe anaphylaxis after subsequent allergen exposures. This argues for the lifelong persistence of allergen-specific memory B cells that can be activated by allergen or potentially also by an inflammatory environmental stimulus 48 to reconstitute the IgE 1 PC compartment. These findings provide an explanation for why certain food allergies can last for a lifetime. They also raise the possibility that subclinical allergen exposures, whether unintended or intended (as might be the case for allergen immunotherapy), might be sufficient to fully regenerate and/or perpetuate disease. In this regard allergen-specific memory lymphocytes have been detected in patients with peanut allergy after 12 to 24 months of oral immunotherapy. 49 The dynamics that control the fate of memory B cells during secondary responses to foods remain largely unexplored. 24 We showed that T H 2 mucosal sensitization generated local and systemic, long-lasting, antigen-specific memory B cells that expanded on mucosal or systemic allergen exposure. The expansion of IgG 1 1 memory B cells was accompanied by BM reconstitution with antigen-specific IgE 1 PCs, whereas the population of IgG 1 1 PCs of the same specificity remained unchanged; this implies that the recall response was driven by IgG 1 1 memory B cells that class-switched and differentiated into IgE 1 PCs. Although sequential class-switching from an intermediate IgG-expressing B cell to IgE has been reported in patients with atopic dermatitis 50 and ex vivo tonsil B-cell cultures, 51 the relevance of both direct and sequential class-switching to IgE in patients with food allergy remains to be elucidated. 52, 53 Even though GC activity was induced during the primary immune response (sensitization), it was absent during recall responses. These data reinforce the notion that class-switched memory B cells, rather than IgM 1 B cells, lead the secondary response 54, 55 and suggest that the strength of B-cell receptor allergen binding is a major decision checkpoint for memory B cells. 56 Our data on the activation of recall responses are in agreement with those of a recent publication that showed that in a system involving transfer of splenic B cells from systemically sensitized mice along with CD4 T cells, followed by 2 systemic challenges, food allergy was elicited in naive recipients in a CD4 T cell-dependent manner. 17 Mechanistically, we found that CD4 T cells facilitated B-cell proliferation independently of CD40L interactions, which is in agreement with the low degree of costimulation required by memory CD4 T cells 57 and the absence of GC activity observed during recall responses to Nippostrongylus brasiliensis. 58 Furthermore, we show that CD4 T cell-secreted IL-4 was central for PC proliferation and orchestrated class-switching of IgG 1 1 memory B cells. These data explain observations in models of helminth infection in which serum increases of total IgE on recall were dependent on IL-4. 59 Hence we propose a model of secondary T H 2 responses to food allergens in which class-switched memory B cells are instructed by IL-4-producing CD4 T cells to proliferate and directly become IgE 1 PCs without additional rounds of affinity maturation.
There is a dearth of knowledge regarding the essential events for the maintenance of T H 2 humoral immunity to allergens. Although targeting IgE 1 PCs has been proposed as a potential cure of food allergy, 18, 60 our data show that IgE-mediated clinical reactivity to food allergens is not sustained by BM-resident antigen-specific IgE 1 PCs. Instead, long-lived mucosal and systemic allergen-specific memory B cells, which are critically assisted by IL-4-producing CD4 T cells, replenish the allergen-specific IgE 1 PC compartment on allergen exposure. These findings intimate that lifelong food allergies observed in human subjects might be the consequence of allergen exposures that recurrently activate memory B and CD4 T cells and provide a comprehensive and invaluable roadmap for the precise design of therapeutic interventions. Our findings indicate that efforts to disable the machinery that maintains and activates memory responses can lead to development of transformative therapies for IgE-mediated food allergies. 
Passive sensitization model
Sera from mice with peanut allergy were administered to IgE-deficient mice. The sera were serially transferred through intraperitoneal injection at 200 mL, 300 mL, and 500 mL, with an interval of 48 hours between each administration. Peritoneal lavage was performed with 10 mmol/L ice-cold EDTA in PBS. IgE-bearing peritoneal MCs were quantified by using flow cytometry as CD45 Antibody and drug administration CD4 T-cell depletion was accomplished through 2 to 3 intraperitoneal administrations of 200 mg of anti-CD4 (clone GK1.5, made in house) over a 1-week period. PCs were depleted with BZ (PS-341; Selleckchem, Houston, Tex) through intraperitoneal injections of 40 mg 2 times per week for 3 weeks. Ten percent to 15% mortality was associated with BZ treatment. Proliferating cells were eliminated with CYC (C7397, Sigma-Aldrich) through daily intraperitoneal injection of 1 mg for 5 consecutive days.
E4
Evaluation of proliferation ex vivo and cytokine production Spleens were pressed through 40-mm nylon strainers, and red blood cells were lysed with ACK before being resuspended in RPMI supplemented with 10% FBS, 1% L-glutamine, 1% penicillin/streptomycin, 55 mmol/L 2-mercaptoethanol (21985-023; Gibco, Carlsbad, Calif), 1 mmol/L sodium pyruvate, 10 mmol/L HEPES, and 0.1 mmol/L MEM NEAA (11140, Gibco). Viable cells were counted through Trypan Blue (Gibco) exclusion and resuspended at 8 3 10 6 cells/mL for further CFSE (Sigma) labeling. E5 Eight hundred thousand alive cells were cultured in sextuplicates in medium alone or with 250 mg/mL crude peanut extract, 20 mg/mL anti-IL-4 (BE0045; Bio X cell, West Lebanon, NH), 20 mg/mL anti-CD40L (MedImmune, Gaithersburg, Md), and 20 mg/mL rat IgG 1 isotype control (BE0088, Bio X cell) in flatbottom 96-well plates (BD Biosciences). After 4 to 5 days of culture at 378C and 5% CO 2 , the sextuplicates were pooled, cells were collected for flow cytometric analysis, and cell-free supernatants were stored at 2808C until further analysis. Cytokines in cell-free supernatants were quantified by using Luminex (Millipore, Temecula, Calif).
Adoptive transfer model
Spleens from mice with OVA allergy and naive mice were harvested and processed under sterile conditions, as described above. Some groups were subjected to in vivo CD4 T-cell depletion, as described above. Once processed, 20 3 10 6 alive splenocytes were injected intravenously in a total volume of 400 mL into recipient immunodeficient Rag2 2/2 gc 2/2 . Recipient mice were gavaged with 1 mg of OVA 3 times a week for 3 weeks. After the last gavage, the mice rested 8 to 10 days before blood was collected and clinical reactivity was evaluated.
